404-409Giardia
intestinalis is the
etiological agent of giardiasis, a common human intestinal
disease with 280 million cases per year. Giardiasis
is typically treated with the broad-range antibiotic metronidazole; however, the
emergence of
drug-resistant strains calls for the development of new anti-parasitic drugs.
Very little is known regarding the molecular mechanisms adopted by Giardia
to cope with the oxidative/nitrosative environmental stress, encountered by the
parasite during colonization of the human intestine. Giardia is
particularly sensitive to oxidative stress, as it lacks some of
the most common ROS-detoxifying enzymes and it is endowed with O2-labile
key metabolic enzymes. Surprisingly,
it colonizes a fairly aerobic (up to 50 M O2) tract of the
human gut (the upper part of the small intestine). Accordingly, survival of the
parasite relies on antioxidant systems, though, as yet, the only two H2O-forming and O2-consuming
enzymes described in Giardia are NADH oxidase and flavodiiron protein
(FDP). Nitric oxide (NO) is an antimicrobial agent produced, together with ROS,
by the host immune system to fight pathogens. In vitro NO-stress has
been reported to have cytostatic, rather than cytotoxic, effects
on Giardia. This effect leads to the suggestion that Giardia is
endowed with defense mechanisms against NO and, very recently, the
NO-detoxifying flavohemoglobin from it has been characterized